Company intelligence / Profile preview

Response Therapeutics

Falls Church, Virginia, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

RDX-002 achieved primary endpoint in Phase 1b clinical trial for Antipsychotic-Induced Weight Gain. Currently conducting Phase 2 study evaluating RDX-002 in patients discontinuing GLP-1 agonists with early completion of enrollment announced in February 2025.

Therapeutic areas: Metabolic DisordersPsychiatryEndocrinology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

ATRN-119

Phase 1

Indications: Advanced solid tumors

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Response Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Response Therapeutics.

Explore the full profile